1. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7(6):504–16.
2. Hogan Lovells. China: progress on conditional approval and compassionate use of new drugs. 2018. https://www.engage.hoganlovells.com/knowledgeservices/news/the-china-food-and-drug-administration-pushes-forward-on-conditional-approval-and-compassionate-use-of-new-drugs. Accessed 10 Aug 2021.
3. National Medical Products Administration. ORPATHYS: NMPA approval notice. 2021. https://www.nmpa.gov.cn/yaowen/ypjgyw/20210623094324131.html. Accessed 10 Aug 2021.
4. Hutchmed. Savolitinib: Chinese prescribing information. Shanghai: Hutchmed; 2021.
5. Hutchison China MediTech Limited. HUTCHMED: Change of company name [media release]. 4 May 2021.